H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis

Portal Vein Thrombosis Clinical Trial

Official title:

Efficacy and Safety of Recombinant Human Adenovirus Type 5 Injection in Combination With TACE-based Combination Therapy in Patients With Stage IIIa Primary Hepatocellular Carcinoma With Portal Vein Thrombosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05872841
• Other study ID #: EC-2023-0009
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 1, 2023
• Est. completion date: June 30, 2025

Study information

• Verified date: July 2022
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: Tongguo Si
• Phone: 18622228655
• Email: drsitg[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is the first to compare the efficacy and safety of recombinant human adenovirus type 5 injection via hepatic artery infusion combined with TACE-based combination therapy for the treatment of patients with stage IIIa primary hepatocellular carcinoma with portal vein carcinoma thrombosis, providing a safe and reliable treatment method for the clinical treatment of this group of patients, and also providing a reference and basis for the treatment of other tumors with this new treatment model.

Description:

This is a prospective, single-arm study to evaluate the efficacy and safety of recombinant human adenovirus type 5 injection combined with TACE-based combination therapy in patients with stage IIIa primary hepatocellular carcinoma with portal vein carcinoma thrombosis. Subjects will be examined and evaluated at the study center, and after meeting the inclusion criteria, patients will be enrolled in a combination of recombinant human adenovirus type 5 injection via hepatic artery infusion and TACE regimen. The study is divided into screening period, baseline period, treatment period, and follow-up period. Follow-up after the end of treatment will be every 3 months until death or the end of this study. The primary study endpoint of this study is disease control rate (DCR) (up to 1 year), while progression free survival (PFS) (up to 1 year), 1-year overall survival rate, and distant metastasis rate are observed, and adverse events occurring during the study period are monitored for safety Data analysis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 38
• Est. completion date: June 30, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age = 18 years and = 75 years, regardless of gender;

2. Patients with stage IIIa primary liver cancer diagnosed by histology or imaging;

3. ECOG physical status score of 0-1;

4. Expected survival time = 3 months;

5. Received no liver protective and supportive treatment within two weeks before enrollment, and met the following conditions:

• White blood cell count =3.0×109/L, neutrophil absolute value =3.0×109/L, platelet count =50×109/L, hemoglobin > 100g/L;

• INR=1.5 and APTT=1.5 upper limit of normal or partial prothrombin time (PTT) =1.5 upper limit of normal;

• Total bilirubin (TBIL) =2.5 times the upper limit of normal value; ALT and AST=5 times the upper limit of normal value; Serum creatinine =1.5 times the upper limit of normal value;

• Creatinine clearance =50ml/min.

6. Voluntary participation in this study and signing of the informed consent form;

7. Female patients of childbearing age or male patients whose sexual partners are women of childbearing age are required to use effective contraception throughout the treatment period and for 6 months after the last dose.

Exclusion Criteria:

1. Pregnant or lactating women, men or women who do not wish to use effective contraception;

2. Patients who have received previous treatment with lysoviruses (e.g., T-VEC), interventional therapy, or TACE;

3. Those who are being treated with antiviral drugs;

4. having received any other experimental drug, antimicrobial drug, or participated in another interventional clinical trial within 4 weeks prior to enrollment

5. Those with a known allergy to the study drug or its active ingredient, or a history of allergy to similar biological agents

6. Evidence of Child-Pugh C hepatic function or hepatocellular dysregulation, including those with refractory ascites, ruptured esophageal or gastric variceal bleeding, and hepatic encephalopathy

7. presence of a history of immunodeficiency or autoimmune disease or long-term systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to enrollment

8. With any unstable systemic disease, including but not limited to: severe infection, hypertensive patients, uncontrolled diabetes mellitus, unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia, abnormal mental status or active cerebral hemorrhage, myocardial infarction, congestive heart failure, severe arrhythmias requiring drug therapy, renal or metabolic disease, severe hepatic dysfunction (including severe jaundice, hepatic encephalopathy, refractory ascites or hepatorenal syndrome), multiple organ failure with renal dysfunction;

9. Previous or concurrent other malignancies;

10. Combined medical contraindications that preclude any contrast-enhanced imaging (CT or MRI);

11. Other conditions that, in the judgment of the investigator, make the patient unsuitable for participation in this study.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Portal Vein Thrombosis
• Primary Hepatocellular Carcinoma
• Thrombosis
• Venous Thrombosis

Intervention

Drug:
• Recombinant human adenovirus type 5 + TACE
Recombinant human adenovirus type 5 : Recombinant human adenovirus type 5 injection is administered intratumorally 48-72h prior to TACE treatment.Before administration, the recombinant human adenovirus type 5 injection was diluted to 30% of the total tumor volume with normal saline. H101 dose: ? The sum of the maximum diameters of the lesions was =10cm, and the total dose was 1. 0×1012vp (2 injections); ? The sum of the maximum diameters of the lesions was >10cm, and the total dose was 1. 5×1012vp (3 injections); TACE:The specific chemotherapeutic drugs were: oxaliplatin 85mg/m2, calcium folinic acid 400mg/m2, 5-fluorouracil 1200mg/m2, followed by superfluid iodinated oil bolus according to the intraoperative contrast tumor blood supply. Recombinant human adenovirus type 5 was administered in combination with TACE in cycles of every 3 weeks for a total of 2-4 cycles.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Medical University Cancer Institute and Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	disease control rate (DCR)	The percentage of patients whose tumors shrank or stabilized and remained for a certain period of time, including cases in complete remission (CR), partial remission (PR), and stable (SD)	Up to 1 year
Secondary	progress free survival(PFS)	The time between the start of randomization and the onset of (any aspect of) tumor progression or death (from any cause)	Up to 1 year
Secondary	overall survival(OS)	The time from randomization to death (from any cause)	Up to 1 year